BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Bristol-Myers Squibb Company 

345 Park Avenue

New York  New York  10154  U.S.A.
Phone: 212-546-4000 Fax: 212-546-4020


SEARCH JOBS




 Key Statistics


Email:
Ownership: Public

Web Site: Bristol-Myers Squibb Company
Employees:
Symbol: BMY
 





Collaborations

Gilead Sciences, Inc. 

PanVera LLC 

Pharmagene Laboratories Limited 

Johnson & Johnson 

Amersham Biosciences 

Lexicon Genetics Incorporated 

Athersys, Inc.  Athersys will provide Bristol-Myers Squibb with cell lines expressing validated drug targets produced using the RAGE-Validated Target technology. BMS plans to use its combinatorial chemistry capabilities to develop small molecule drug candidates against the validated targets.

Merck & Co.  Diabetes

Affinimark Technologies Inc. 

GlaxoSmithKline (North Carolina) 

Medarex, Inc. 

Gilead Sciences, Inc. (Durham, NC) 

Phyton Biotech, Inc.  - Cancer

Gilead Sciences, Inc. (Seattle, WA) 





 Company News
Bristol-Myers Squibb Company (BMY) Receives Accelerated Approval Of Opdivo (Nivolumab) From The FDA 12/23/2014 6:10:58 AM
FDA Grants Accelerated Approval for Bristol-Myers Squibb Company (BMY)'s Skin Cancer Drug Opdivo 12/23/2014 6:10:02 AM
Fitch Revises Bristol-Myers Squibb Company (BMY)'s Outlook To Stable; Affirms IDR At "A-" 12/12/2014 9:52:40 AM
Ono Pharmaceutical Company, Ltd., Bristol-Myers Squibb Company (BMY), And Kyowa Hakko Kirin Announce Immuno-Oncology Clinical Collaboration Studying Opdivo (Nivolumab) And Mogamulizumab In Advanced Solid Tumors 12/10/2014 9:19:38 AM
Bristol-Myers Squibb Company (BMY) Release: Anticoagulant Effect Of Eliquis (Apixaban) Reversed By Two Separate 4-Factor Prothrombin Complex Concentrates In Healthy Subjects 12/9/2014 11:13:44 AM
Bristol-Myers Squibb Company (BMY) Release: Opdivo (nivolumab) Demonstrates High Overall Response Rate Of 87% for Treatment Of Relapsed Or Refractory Hodgkin Lymphoma 12/8/2014 2:38:44 PM
FDA Requires Additional Data On Bristol-Myers Squibb Company (BMY)' Hep C Daclatasvir 11/26/2014 11:26:36 AM
Bristol-Myers Squibb Company (BMY) Release: ELIQUIS Approved For Treatment Of Venous Thromboembolic Events (Deep Vein Thrombosis [DVT], Pulmonary Embolism [PE]) And Prevention Of Recurrent DVT And PE 11/26/2014 10:57:24 AM
Bristol-Myers Squibb Company (BMY) Release: Analyses From Phase 3b Study Provide Additional Data In Earlier Use Of Orencia (Abatacept) Plus Methotrexate (MTX) In Citrullinated Protein (CCP)-Positive Adult Patients With Early Rheumatoid Arthritis (RA) 11/17/2014 12:54:55 PM
Bristol-Myers Squibb Company (BMY) Release: Study Comparing Opdivo (Nivolumab) To Chemotherapy In Treatment Naïve Advanced Melanoma Patients Marks First PD-1 Immune Checkpoint Inhibitor To Demonstrate A Survival Benefit In A Phase 3 Trial 11/17/2014 11:55:24 AM
12345678910...